CYP2D6
Researchers have developed a computational method that considers uncommon CYP2D6 variants to assess patient-specific metabolism of tamoxifen and other drugs.
AMP-led Expert Groups Release Clinical CYP2D6 Pharmacogenomic Testing Recommendation
The consensus guideline offers a two-tier categorization of alleles that are recommended for clinical CYP2D6 pharmacogenetic testing.
The program uses an informatics system that converts genotype results to "traffic lights" telling clinicians whether a drug is acceptable for a certain patient.
Data shows CYP2D6 testing in breast tumor tissue can be inaccurate due to loss of heterozygosity, and may have obscured the connection between genotype and tamoxifen response in previous trials.
The new RUO application for the company's QuantStudio 3D Digital PCR platform is designed to enable researchers to accurately phenotype the CYP2D6 gene, a key indicator of drug metabolism.